Case question of roche
•Download as PPT, PDF•
1 like•2,276 views
This document contains questions about Roche's acquisition of Genentech shares: 1) Roche is seeking the remaining 44% of Genentech shares to gain full ownership of the company. 2) Owning 100% would give Roche full control and synergies, but risks include losing a public listing and takeover premium. 3) As majority shareholder, Roche must protect minority shareholders' interests. 4) Roche estimated $600 million in annual synergies from the merger in June 2008.
Report
Share
Report
Share
Recommended
Roche holding AG: Genentech Acquisition
Roche, a Swiss pharmaceutical company, made an offer to acquire all remaining shares of Genentech, a US biotechnology company, for $89 per share. After equity markets declined 35%, Roche lowered its offer to $86.50 per share. To fund the $42 billion deal, Roche planned to sell $32 billion in bonds in US dollars, euros, and British pounds. However, undertaking such a large bond offering during a time of significant turmoil in global credit markets increased the complexity and risk of financing the acquisition.
Roche's Acquisition of Genentech
TD Mergers & Acquisitions Competition 2015
We created a presentation on the potential bid structure and analysis of the transaction based on HBS case 9-210-040 "Roche's Acquisition of Genentech".
Team members:
Catherine Qian
Jenny Li
Terence Leung
Yu Cao
M a analysis_roche_genentech
This document analyzes Roche's potential acquisition of Genentech. It discusses Roche's choices to either concede but negotiate a higher price, make a tender offer directly to shareholders, or wait in hopes that a new cancer drug fails which would lower Genentech's value. It then provides valuations of Genentech from $78-115 per share and compares to other company multiples. Finally, it describes how the acquisition progressed from hostile to friendly after Roche raised its offer price.
ppt
This document compares the performance of several investment funds over different time periods ranging from 1 year to 10 years. It provides the annual returns, standard deviation, and beta for each fund compared to the S&P 500 index. The Science & Tech fund had the highest returns over 3, 5, 7, and 10 year periods but also the highest standard deviation, meaning it was the most volatile. The Core Investment and Accumulative funds had returns close to the S&P 500 but with lower standard deviation, making them less risky options.
RRSP_Contribution
This document provides historical performance data for 12 investment equities that can be selected for contributions to a RRSP (Canada's equivalent to a 401K). An algorithm is described that uses modern portfolio theory to determine an optimal asset weighting across the 12 equities to maximize return for a given level of risk, known as the efficient frontier. The document demonstrates calculating the efficient frontier for a sample data set and stresses the importance of monitoring investments and ensuring the portfolio remains on the efficient frontier over time.
Smart Beta - Lessons from the Oracle of Omaha
This document summarizes lessons from Warren Buffett's investing approach at Berkshire Hathaway. Some key points:
1) Berkshire significantly outperformed the market over decades with lower risk, due to factor exposures like value, quality and beta rather than stock picking ability.
2) Factor premiums are not guaranteed and vary over time, so a disciplined, diversified approach balancing multiple factors is important to manage risks and stay invested for the long term.
3) Closet index strategies may not truly capture intended factors. Investors need to understand the methodology and holdings to confirm the strategy matches its objectives.
No Silver Bullets Presentation
In a lower expected return environment, should we just accept lower withdrawal rates?
In this presentation, we outline 8 simple ideas that when used together can potentially help make up the return gap.
Risk return-results
Mutual Fund SIP and Lump sum returns along with risk-return anlysis scores for durations ranging 1Y to 8Y. Created with a free excel template available at freefincal.com
Recommended
Roche holding AG: Genentech Acquisition
Roche, a Swiss pharmaceutical company, made an offer to acquire all remaining shares of Genentech, a US biotechnology company, for $89 per share. After equity markets declined 35%, Roche lowered its offer to $86.50 per share. To fund the $42 billion deal, Roche planned to sell $32 billion in bonds in US dollars, euros, and British pounds. However, undertaking such a large bond offering during a time of significant turmoil in global credit markets increased the complexity and risk of financing the acquisition.
Roche's Acquisition of Genentech
TD Mergers & Acquisitions Competition 2015
We created a presentation on the potential bid structure and analysis of the transaction based on HBS case 9-210-040 "Roche's Acquisition of Genentech".
Team members:
Catherine Qian
Jenny Li
Terence Leung
Yu Cao
M a analysis_roche_genentech
This document analyzes Roche's potential acquisition of Genentech. It discusses Roche's choices to either concede but negotiate a higher price, make a tender offer directly to shareholders, or wait in hopes that a new cancer drug fails which would lower Genentech's value. It then provides valuations of Genentech from $78-115 per share and compares to other company multiples. Finally, it describes how the acquisition progressed from hostile to friendly after Roche raised its offer price.
ppt
This document compares the performance of several investment funds over different time periods ranging from 1 year to 10 years. It provides the annual returns, standard deviation, and beta for each fund compared to the S&P 500 index. The Science & Tech fund had the highest returns over 3, 5, 7, and 10 year periods but also the highest standard deviation, meaning it was the most volatile. The Core Investment and Accumulative funds had returns close to the S&P 500 but with lower standard deviation, making them less risky options.
RRSP_Contribution
This document provides historical performance data for 12 investment equities that can be selected for contributions to a RRSP (Canada's equivalent to a 401K). An algorithm is described that uses modern portfolio theory to determine an optimal asset weighting across the 12 equities to maximize return for a given level of risk, known as the efficient frontier. The document demonstrates calculating the efficient frontier for a sample data set and stresses the importance of monitoring investments and ensuring the portfolio remains on the efficient frontier over time.
Smart Beta - Lessons from the Oracle of Omaha
This document summarizes lessons from Warren Buffett's investing approach at Berkshire Hathaway. Some key points:
1) Berkshire significantly outperformed the market over decades with lower risk, due to factor exposures like value, quality and beta rather than stock picking ability.
2) Factor premiums are not guaranteed and vary over time, so a disciplined, diversified approach balancing multiple factors is important to manage risks and stay invested for the long term.
3) Closet index strategies may not truly capture intended factors. Investors need to understand the methodology and holdings to confirm the strategy matches its objectives.
No Silver Bullets Presentation
In a lower expected return environment, should we just accept lower withdrawal rates?
In this presentation, we outline 8 simple ideas that when used together can potentially help make up the return gap.
Risk return-results
Mutual Fund SIP and Lump sum returns along with risk-return anlysis scores for durations ranging 1Y to 8Y. Created with a free excel template available at freefincal.com
Quotemonster roadshow session two June 2019
Copy of the slides used in the second of two Quotemonster workshops in May and June 2019. Date of upload is 26 July 2019. Material current in June. Note research is dynamic, and has been revised even during the period of the workshops - you must be a financial adviser and access the live site to use the research. If you are a consumer, please be aware that this is training material and has already been superseded on the live site. Please refer to a financial adviser for advice.
Building an Unconstrained Sleeve
Combining unconstrained and tactical investment strategies to seek hedging, equity-like, and absolute-return style investment exposure.
Explores how to combine tactical equity, minimum volatility, managed futures, risk parity, and other approaches.
Pharmacy Services Sector
This document provides an overview of an industry study on pharmacy services. It discusses how different rating agencies classify the industry. It also notes that CVS and Walgreens are considered conglomerates as they have pharmacies, clinics, and drug plans. The document recommends researching the industry online and reviewing reports from S&P, Value Line, and other sources to get a full picture. Key takeaways identified include an aging population boosting prescription drug use, a competitive industry with low margins, and ongoing mergers and acquisitions.
Are bonds in a bubble?
Newfound Research was founded in 2008 based on the premise of capital preservation for investors. The company believes in portfolio processes that are simple, consistent, and thoughtfully designed, with managing risk being paramount. Newfound Research focuses on defensive, simple, consistent, and thoughtful investment philosophies and strategies. The documents provides an overview of Newfound Research's investment philosophy and approach to risk management. It also discusses concepts like asset bubbles, bond valuations, equity valuations, and the benefits of diversification in periods of low expected future returns for traditional stock and bond portfolios.
Proctor&Gamble
- Procter & Gamble (PG) is currently trading at $71.70 per share with an analyst target price of $78 over the next 2 years. The top shareholders are institutions and funds which own over 90% of shares. Analyst consensus is overweight with more buy ratings than holds or sells.
- PG operates through five segments and generates over $70 billion in annual revenue. Recent earnings have met estimates but revenue growth has been negative. However, the company maintains a strong dividend yield of over 3%.
- Upside potential comes from stock buybacks, earnings growth from restructuring, and a lower relative P/E. However, risks include exposure to slowing consumer markets and international currencies.
Investment Policy for Insurers - June 2012
Investment policy decisions are a vital part of a successful investment process for insurers. Related to this: Strategic asset allocation and how best to manage in a low interest rate environment.
Dividend Weekly 49 2012 By http://long-term-investments.blogspot.com
The Dividend Weekly is a weekly published Fact Book with focus on dividend stocks. With this book, investors get a full overview of major leaders and laggards. In addition, they get a feeling of which dividend stocks are popular and which ones are the best investment opportunities in markets that are going up and down.
The book has the following items:
- Best 1-Week Performing Dividend Stocks
- Best Dividend Stocks Year-To-Date
- Best Yielding Stocks At New Highs
- Most Recommended Dividend Stocks
- Overbought Dividend Stocks
- Most Shorted Dividend Stocks
- Best Dividend Aristocrats in Canada and USA
- Stocks With Dividend Growth From Last Week
- Best Yielding Stocks From the World's Leading Stock Exchanges and Indices
- Ex-Dividend Stocks For Next Week
Thanks to http://long-term-investments.blogspot.com
Back to the future
The document discusses various topics related to investing in equities such as past performance of equities, importance of asset allocation and diversification, and strategies for building a pension plan. It provides statistics showing that equities have generated predictable positive returns over long periods of time. It also emphasizes that proper selection of investments, understanding risk and return, and staying invested are keys to investment success. The document advocates for diversification across asset classes like equity, bonds and gold to reduce risk and enhance returns over time.
IDFC Bond Fund Income Plan_Fund spotlight
This fund is an actively managed medium to long term bond fund that seeks to generate stable returns through accrued income and capital appreciation by investing in highly rated money market and debt instruments, including government securities. The fund has a Macaulay duration between 4-7 years and primarily invests in AAA rated government bonds, with over 96% allocated to various government securities. It provides monthly dividend and growth options to investors seeking optimal returns over the long term through investments in debt and money market securities with a duration of 4-7 years.
The State of Risk Management
How effective is your method of managing portfolio risk? We compare and contrast different approaches – including fixed income, managed futures, low volatility equities, and tactical – to explore the relative protection they can deliver versus the return drag they can create.
FTSE RAFI webinar Mar 20
The document summarizes a presentation on the 10 year anniversary of the FTSE RAFI Index Series. It discusses how fundamental indexing was originally conceived as an alternative to cap-weighted indexing and active management. It then reviews how the original criticisms of fundamental indexing have held up based on 10 years of live performance data. Finally, it discusses how fundamental indexing has evolved and the future of smart beta strategies.
From the clinic to the cfo adaptive trials and financial decision making
This document discusses how adaptive trial designs can be used to integrate clinical trial planning with financial decision making. It presents two case studies:
1) A biotech company used an adaptive design for a pivotal trial of an AML drug to reduce upfront costs and attract external investment. Interim results determined whether to increase the sample size. This improved the drug's risk/reward profile.
2) Hypothetical options for developing a niche oncology asset were evaluated. Scenarios including group sequential designs with interim analyses provided trade-offs between probability of success, time, cost, and expected value to discuss with management. Integrating financial metrics into adaptive trial design allows more flexible, "investable" research options.
FiBAN's business angel training "Business Angel Returns" by Robert Wiltbank -...
Presention shared by Dr. Robert Wiltbank at FiBAN's business angel training in Helsinki, 3rd of November.
All the presentations and videos are gathered here: https://www.fiban.org/robertwiltbank
Presentations given:
1. Comparison of Finnish and US angel activity
https://www.youtube.com/watch?v=UKdmr...
- Slides:
2. Angel Returns: https://www.youtube.com/watch?v=juuAK...
- Slides:
3. Effective business angel strategies: https://www.youtube.com/watch?v=TsZQd...
- Slides:
4. Effectuation in Venture investing - Do experts make decisions differently?: https://www.youtube.com/watch?v=miWap...
- Slides
For additional details and questions: https://www.fiban.org/robertwiltbank
ALPS Tear sheet Alps YTD jan 2017
- The document describes an investment strategy focused on preferred stocks that aims to provide attractive risk-adjusted returns uncorrelated to fixed income and equities, with lower volatility than stocks.
- Performance statistics for 2016-2015 show the strategy outperforming the S&P 500 with lower standard deviation, while the fund structure details management and redemption terms.
- Charts show the strategy's NAV growth and rolling 12-month returns, demonstrating compound returns since inception in 2014.
Safe Patch - Do you know where your loved ones have wandered off to?
Team Safe Patch – 1st Place
Shawn Lee, Jeff Lai, Shoko Takahashi, Dorian Buksz, Benjamin Eu
Class 3, MIT Global Entrepreneurship Bootcamp Seoul Demo Day
March 25, 2016
About the program
The MIT Global Entrepreneurship Bootcamp is an intensive, week-long new ventures leadership program that gives bootcampers a taste of drinking from the firehose that all MIT students experience. It is a nexus connecting entrepreneurs from around the world to the entrepreneurship and innovation eco-system surrounding the Massachusetts Institute of Technology.
https://bootcamp.mit.edu/entrepreneurship
M&A Case Competition presentation
The acquisition of Genentech by Roche would provide several strategic benefits. It would increase Roche's market power in the biotechnology industry by acquiring Genentech's large market share and barrier to market entry. The acquisition also reduces Roche's financial and operational risks by diversifying its product portfolio. Synergies from cost cutting and new opportunities could generate an estimated net present value of $3.09 billion for Roche. Based on discounted cash flow, comparable company, and precedent transaction analyses, the estimated enterprise value for Genentech is $107 billion, implying an acquisition offer price of $98 per share.
Roche Genentech Acquisition Analysis
This document provides an overview of Genentech, a biotechnology company, in 3 sections:
1. It outlines Genentech's origins in the 1970s through scientific innovations in genetic engineering and being the first to clone human proteins in bacteria.
2. It describes Genentech's leadership in the biotherapeutics industry through the 1990s-2000s via FDA approvals, research capabilities, manufacturing expertise, and strategic partnerships.
3. It analyzes Genentech's value-based management strategies including clear goals, emphasis on scientific excellence, skilled personnel, and streamlined systems that have led to consistent financial outperformance of industry averages.
Genentech
A presentation of Genentech strategic growth options vis-a-vis the current economic and structural challenges the biotech industry is facing.
Team project, December 2008.
Genentech ppt (2)
Genentech created an innovative work culture that emphasized freedom, flexibility, and an informal atmosphere to attract top scientists and researchers. They offered competitive benefits and perks like discretionary work time, learning opportunities, recognition programs, and an emphasis on diversity and inclusion. However, as the company grew larger there was a risk it could lose elements of its small, collaborative culture that made it unique.
BA401_Genentech
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient capacity through 2015 while balancing risks and costs.
Molecualr diagnostics ,comparison with roche hbv kit
This study evaluated a novel domestic hepatitis B virus (HBV) DNA quantitative fluorescence diagnostic kit and compared it to the Roche Cobas Ampliprep/COBAS Taqman HBV test kit. The kits were evaluated based on traceability, accuracy, precision, and clinical performance using WHO HBV DNA standards, standard HBV B and C genotype plasma samples, and clinical serum samples. Results showed no significant differences between the kits in traceability, accuracy, precision, or clinical detection. Both kits agreed with the WHO standard across tested titers and showed acceptable deviation from expected values for accuracy. Precision and clinical sample testing also showed good agreement between the two kits.
Roche diagnostics 2 9-11 - no speaker notes
The document discusses an eMarketing company's capabilities for interactive digital experiences. It outlines the company's approach of focusing on superior user experience through 1:1 marketing and active learning. Examples of its work include programs targeted at OB/GYNs. The company has a large HCP database and proprietary DIAGRAM software. Its core philosophy is delivering superior user experiences through design, functionality, and active learning principles that build meaningful relationships.
More Related Content
What's hot
Quotemonster roadshow session two June 2019
Copy of the slides used in the second of two Quotemonster workshops in May and June 2019. Date of upload is 26 July 2019. Material current in June. Note research is dynamic, and has been revised even during the period of the workshops - you must be a financial adviser and access the live site to use the research. If you are a consumer, please be aware that this is training material and has already been superseded on the live site. Please refer to a financial adviser for advice.
Building an Unconstrained Sleeve
Combining unconstrained and tactical investment strategies to seek hedging, equity-like, and absolute-return style investment exposure.
Explores how to combine tactical equity, minimum volatility, managed futures, risk parity, and other approaches.
Pharmacy Services Sector
This document provides an overview of an industry study on pharmacy services. It discusses how different rating agencies classify the industry. It also notes that CVS and Walgreens are considered conglomerates as they have pharmacies, clinics, and drug plans. The document recommends researching the industry online and reviewing reports from S&P, Value Line, and other sources to get a full picture. Key takeaways identified include an aging population boosting prescription drug use, a competitive industry with low margins, and ongoing mergers and acquisitions.
Are bonds in a bubble?
Newfound Research was founded in 2008 based on the premise of capital preservation for investors. The company believes in portfolio processes that are simple, consistent, and thoughtfully designed, with managing risk being paramount. Newfound Research focuses on defensive, simple, consistent, and thoughtful investment philosophies and strategies. The documents provides an overview of Newfound Research's investment philosophy and approach to risk management. It also discusses concepts like asset bubbles, bond valuations, equity valuations, and the benefits of diversification in periods of low expected future returns for traditional stock and bond portfolios.
Proctor&Gamble
- Procter & Gamble (PG) is currently trading at $71.70 per share with an analyst target price of $78 over the next 2 years. The top shareholders are institutions and funds which own over 90% of shares. Analyst consensus is overweight with more buy ratings than holds or sells.
- PG operates through five segments and generates over $70 billion in annual revenue. Recent earnings have met estimates but revenue growth has been negative. However, the company maintains a strong dividend yield of over 3%.
- Upside potential comes from stock buybacks, earnings growth from restructuring, and a lower relative P/E. However, risks include exposure to slowing consumer markets and international currencies.
Investment Policy for Insurers - June 2012
Investment policy decisions are a vital part of a successful investment process for insurers. Related to this: Strategic asset allocation and how best to manage in a low interest rate environment.
Dividend Weekly 49 2012 By http://long-term-investments.blogspot.com
The Dividend Weekly is a weekly published Fact Book with focus on dividend stocks. With this book, investors get a full overview of major leaders and laggards. In addition, they get a feeling of which dividend stocks are popular and which ones are the best investment opportunities in markets that are going up and down.
The book has the following items:
- Best 1-Week Performing Dividend Stocks
- Best Dividend Stocks Year-To-Date
- Best Yielding Stocks At New Highs
- Most Recommended Dividend Stocks
- Overbought Dividend Stocks
- Most Shorted Dividend Stocks
- Best Dividend Aristocrats in Canada and USA
- Stocks With Dividend Growth From Last Week
- Best Yielding Stocks From the World's Leading Stock Exchanges and Indices
- Ex-Dividend Stocks For Next Week
Thanks to http://long-term-investments.blogspot.com
Back to the future
The document discusses various topics related to investing in equities such as past performance of equities, importance of asset allocation and diversification, and strategies for building a pension plan. It provides statistics showing that equities have generated predictable positive returns over long periods of time. It also emphasizes that proper selection of investments, understanding risk and return, and staying invested are keys to investment success. The document advocates for diversification across asset classes like equity, bonds and gold to reduce risk and enhance returns over time.
IDFC Bond Fund Income Plan_Fund spotlight
This fund is an actively managed medium to long term bond fund that seeks to generate stable returns through accrued income and capital appreciation by investing in highly rated money market and debt instruments, including government securities. The fund has a Macaulay duration between 4-7 years and primarily invests in AAA rated government bonds, with over 96% allocated to various government securities. It provides monthly dividend and growth options to investors seeking optimal returns over the long term through investments in debt and money market securities with a duration of 4-7 years.
The State of Risk Management
How effective is your method of managing portfolio risk? We compare and contrast different approaches – including fixed income, managed futures, low volatility equities, and tactical – to explore the relative protection they can deliver versus the return drag they can create.
FTSE RAFI webinar Mar 20
The document summarizes a presentation on the 10 year anniversary of the FTSE RAFI Index Series. It discusses how fundamental indexing was originally conceived as an alternative to cap-weighted indexing and active management. It then reviews how the original criticisms of fundamental indexing have held up based on 10 years of live performance data. Finally, it discusses how fundamental indexing has evolved and the future of smart beta strategies.
From the clinic to the cfo adaptive trials and financial decision making
This document discusses how adaptive trial designs can be used to integrate clinical trial planning with financial decision making. It presents two case studies:
1) A biotech company used an adaptive design for a pivotal trial of an AML drug to reduce upfront costs and attract external investment. Interim results determined whether to increase the sample size. This improved the drug's risk/reward profile.
2) Hypothetical options for developing a niche oncology asset were evaluated. Scenarios including group sequential designs with interim analyses provided trade-offs between probability of success, time, cost, and expected value to discuss with management. Integrating financial metrics into adaptive trial design allows more flexible, "investable" research options.
FiBAN's business angel training "Business Angel Returns" by Robert Wiltbank -...
Presention shared by Dr. Robert Wiltbank at FiBAN's business angel training in Helsinki, 3rd of November.
All the presentations and videos are gathered here: https://www.fiban.org/robertwiltbank
Presentations given:
1. Comparison of Finnish and US angel activity
https://www.youtube.com/watch?v=UKdmr...
- Slides:
2. Angel Returns: https://www.youtube.com/watch?v=juuAK...
- Slides:
3. Effective business angel strategies: https://www.youtube.com/watch?v=TsZQd...
- Slides:
4. Effectuation in Venture investing - Do experts make decisions differently?: https://www.youtube.com/watch?v=miWap...
- Slides
For additional details and questions: https://www.fiban.org/robertwiltbank
ALPS Tear sheet Alps YTD jan 2017
- The document describes an investment strategy focused on preferred stocks that aims to provide attractive risk-adjusted returns uncorrelated to fixed income and equities, with lower volatility than stocks.
- Performance statistics for 2016-2015 show the strategy outperforming the S&P 500 with lower standard deviation, while the fund structure details management and redemption terms.
- Charts show the strategy's NAV growth and rolling 12-month returns, demonstrating compound returns since inception in 2014.
Safe Patch - Do you know where your loved ones have wandered off to?
Team Safe Patch – 1st Place
Shawn Lee, Jeff Lai, Shoko Takahashi, Dorian Buksz, Benjamin Eu
Class 3, MIT Global Entrepreneurship Bootcamp Seoul Demo Day
March 25, 2016
About the program
The MIT Global Entrepreneurship Bootcamp is an intensive, week-long new ventures leadership program that gives bootcampers a taste of drinking from the firehose that all MIT students experience. It is a nexus connecting entrepreneurs from around the world to the entrepreneurship and innovation eco-system surrounding the Massachusetts Institute of Technology.
https://bootcamp.mit.edu/entrepreneurship
What's hot (15)
Dividend Weekly 49 2012 By http://long-term-investments.blogspot.com
Dividend Weekly 49 2012 By http://long-term-investments.blogspot.com
From the clinic to the cfo adaptive trials and financial decision making
From the clinic to the cfo adaptive trials and financial decision making
FiBAN's business angel training "Business Angel Returns" by Robert Wiltbank -...
FiBAN's business angel training "Business Angel Returns" by Robert Wiltbank -...
Safe Patch - Do you know where your loved ones have wandered off to?
Safe Patch - Do you know where your loved ones have wandered off to?
Viewers also liked
M&A Case Competition presentation
The acquisition of Genentech by Roche would provide several strategic benefits. It would increase Roche's market power in the biotechnology industry by acquiring Genentech's large market share and barrier to market entry. The acquisition also reduces Roche's financial and operational risks by diversifying its product portfolio. Synergies from cost cutting and new opportunities could generate an estimated net present value of $3.09 billion for Roche. Based on discounted cash flow, comparable company, and precedent transaction analyses, the estimated enterprise value for Genentech is $107 billion, implying an acquisition offer price of $98 per share.
Roche Genentech Acquisition Analysis
This document provides an overview of Genentech, a biotechnology company, in 3 sections:
1. It outlines Genentech's origins in the 1970s through scientific innovations in genetic engineering and being the first to clone human proteins in bacteria.
2. It describes Genentech's leadership in the biotherapeutics industry through the 1990s-2000s via FDA approvals, research capabilities, manufacturing expertise, and strategic partnerships.
3. It analyzes Genentech's value-based management strategies including clear goals, emphasis on scientific excellence, skilled personnel, and streamlined systems that have led to consistent financial outperformance of industry averages.
Genentech
A presentation of Genentech strategic growth options vis-a-vis the current economic and structural challenges the biotech industry is facing.
Team project, December 2008.
Genentech ppt (2)
Genentech created an innovative work culture that emphasized freedom, flexibility, and an informal atmosphere to attract top scientists and researchers. They offered competitive benefits and perks like discretionary work time, learning opportunities, recognition programs, and an emphasis on diversity and inclusion. However, as the company grew larger there was a risk it could lose elements of its small, collaborative culture that made it unique.
BA401_Genentech
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient capacity through 2015 while balancing risks and costs.
Molecualr diagnostics ,comparison with roche hbv kit
This study evaluated a novel domestic hepatitis B virus (HBV) DNA quantitative fluorescence diagnostic kit and compared it to the Roche Cobas Ampliprep/COBAS Taqman HBV test kit. The kits were evaluated based on traceability, accuracy, precision, and clinical performance using WHO HBV DNA standards, standard HBV B and C genotype plasma samples, and clinical serum samples. Results showed no significant differences between the kits in traceability, accuracy, precision, or clinical detection. Both kits agreed with the WHO standard across tested titers and showed acceptable deviation from expected values for accuracy. Precision and clinical sample testing also showed good agreement between the two kits.
Roche diagnostics 2 9-11 - no speaker notes
The document discusses an eMarketing company's capabilities for interactive digital experiences. It outlines the company's approach of focusing on superior user experience through 1:1 marketing and active learning. Examples of its work include programs targeted at OB/GYNs. The company has a large HCP database and proprietary DIAGRAM software. Its core philosophy is delivering superior user experiences through design, functionality, and active learning principles that build meaningful relationships.
Comaprative Study between Abbott and Roche
This document provides a comparative study of Abbott and Roche pharmaceutical companies. It outlines their profiles, missions, values, organizational structures, diversity policies, HR policies, practices, employee engagement, and assessments. The study finds that both companies are committed to their employees and communities, though they differ in some HR strategies. It provides recommendations for each company, noting the need for both to focus on areas like R&D, flexible work, rural outreach, and employee retention. The document concludes that long-term success requires continuous effort, determination, creativity and imagination.
Innovation drives expansion, Titus Gylvin
Roche is the world's largest biotech company and leader in personalized healthcare. It has brought 14 biopharmaceuticals to market based on biotechnology and has over half of new molecules in development for cancer treatments. Roche invests heavily in R&D, with $8.6 billion globally in 2015 - four times Finland's total spending on prescription medicines. It has a strong pipeline of potential new medicines and therapies in development through its own research and over 190 academic and industry partnerships worldwide.
Roche diagnostics sales planning
Roche Diagnostics selected IBM's Cognos TM1 as its new business planning tool after a vendor selection process. The first project using TM1 was for sales planning across 7 countries. Lessons learned were that initial effort estimates were too low and integrating TM1 into Roche's IT landscape took more time than expected. Roche has since expanded usage of TM1 to additional planning projects beyond sales, such as finance planning. The tool provides flexibility and powerful functionality while also needing careful modeling to achieve results quickly.
Conference brochure
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Digital Pathology streamlines tissue diagnostics and helps protect patient sa...
Digital Pathology streamlines tissue diagnostics and helps protect patient sa...Roche Tissue Diagnostics
RZ Tienen Hospital became one of the first hospitals in Belgium, and one of the first in Europe, to implement and integrate digital pathology into daily operations. They have transformed their AP lab and are now able to manage caseloads remotely, facility MDT oncology meetings and enhance collaboration with colleagues. The benefits of digital pathology have been well recognized and RZ Tienen expects continued growth in this area.
Rodney POC
Roche is the market leader in point-of-care diagnostics testing in the US, with the broadest portfolio addressing various customer needs across settings like hospitals, physicians' offices, and patient self-testing. The point-of-care diagnostics market is growing rapidly due to factors like technology advances making lab-quality tests more accessible near patients. Roche's strategy is to drive further decentralization of testing, expand its product offerings, and leverage its leadership position and assets to continue growing market share.
Roche Diagnostics
Roche Diagnostics conducted customer satisfaction surveys to better understand customer needs and identify areas for improvement. They established new customer service initiatives like a toll-free hotline and dedicated customer support teams. Linking customer satisfaction to profits allows Roche to focus on enhancing the customer experience which drives customer loyalty and future sales.
Cipla roche
The Delhi High Court dismissed Roche's appeal against Cipla manufacturing a generic version of erlotinib, Roche's cancer drug sold as Tarceva. Cipla argued Roche's patent was invalid as erlotinib was derived from a known compound and lacked inventive step. The single judge ruled in Cipla's favor based on public interest of affordable access to life-saving drugs. However, the division bench dismissed the appeal based on Roche's failure to disclose the patented drug consisted of a specific polymorph not covered in the patent. The court criticized Roche's lack of full disclosure and testing to prove infringement.
Viewers also liked (18)
Molecualr diagnostics ,comparison with roche hbv kit
Molecualr diagnostics ,comparison with roche hbv kit
Digital Pathology streamlines tissue diagnostics and helps protect patient sa...
Digital Pathology streamlines tissue diagnostics and helps protect patient sa...
Similar to Case question of roche
Anteo Technologies Investor Presentation
This document provides an overview of Anteo Diagnostics and their nanotechnology applications. Anteo has developed a patented nanoglue technology called Mix&Go that can bind biological molecules to synthetic surfaces. They are applying this technology in four business areas: 1) in vitro diagnostics and life sciences markets, 2) bioseparations, 3) medical devices, and 4) batteries. For each area, Anteo's nanoglue can improve functionality, sensitivity, and cost efficiency. The document outlines Anteo's revenue generation process, partnership achievements, and the vast potential of their drop-in nanotechnology.
2011 Global Customer Experience Management Survey
What is Your Competition Doing? Are You an Industry Customer Experience Leader? Join Beyond Philosophy to See the Results of the 2011 Global Customer Experience Management Survey
• Current insights on customer experience from experts and CxOs from across the globe
• Analysis of 8,000 customer experience leaders
Program
Join Steven Walden, Beyond Philosophy's Senior Head of Research, and Colin Shaw, Founder and CEO, as they reveal the results of the 2011 Global Customer Experience Management Survey. The research will pull back the curtain on where the industry stands today, answering questions such as:
• Which industries and regions spend the most on customer experience?
• What are the drivers and challenges the customer experience industry faces as it further develops?
• What companies have seen the biggest customer experience growth, by industry?
• Where is customer experience management most needed? What industry? What country? What companies?
In addition, they discuss topics such as:
• What industries will see the greatest growth in customer experience over the next several years?
• What will be the next great customer experience advancement?
• What is the valuable element of a company's customer experience program? How does it differ by industry or region?
• How will social media affect the way companies approach customer experience?
Learning Objectives
• Learn about the Beyond Philosophy 7-stage Customer Experience Maturity model.
• Discover which industries and countries are concentrating on enhancing the customer experience.
• Learn how to overcome common problems that get in the way of successful customer experiences.
• Explore the pace of growth and the state of customer experience development, broken down by geographic regions.
Anteo Diagnostics ASX Spotlight Presentation March 2014
Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in diagnostics and life sciences. In 2013, Anteo achieved solid commercial progress including partnership agreements that are enhancing the prospects of becoming cash flow positive in 2014. Anteo is now focused on advancing near-term opportunities to generate licensing fees and royalties from Mix&Go and expanding into the large market for bioseparations.
Investing In A World Of Opportunity
This document discusses the benefits of global investing and how to invest globally. It outlines that global markets now account for 50% of total stock market capitalization, so ignoring foreign markets means ignoring half of investment opportunities. Investing globally provides exposure to industries and companies outside the US as well as access to the fastest growing economies. While global investing carries special risks like currency fluctuations and political instability, diversifying across world markets has historically improved risk-adjusted returns. The document recommends investing globally through mutual funds for professional management and simplified transactions, and considering both developed and emerging international markets for long-term growth potential.
Op Risk for Super Funds
This document summarizes the current state of operational risk reserves in the Australian superannuation industry. It discusses the regulatory capital requirements for superannuation trustees, the definition of operational risk reserves, and proposed changes to capital standards. Research on current industry practices found a wide range in reserve levels as a percentage of assets, members, and expenses across funds. The document concludes by considering international practices and next steps for the superannuation sector.
Pfizer at Citi Global Health Care Conference
The document is a presentation from Pfizer's CFO at a healthcare conference in May 2008. It summarizes Pfizer's strategies to: 1) maximize revenues from existing, new, and diverse product sources; 2) establish a lower, more flexible cost base; and 3) innovate its business model. The presentation provides details on optimizing Pfizer's patent-protected portfolio, capitalizing on established products, growing in emerging markets, proven cost management track record, and 2008 financial guidance.
Vietnam Smallholder Pigs Value Chain Component Situation Report 2012
Presented by Lucy Lapar (ILRI) at the Livestock and Fish Value Chain Component Planning Meeting, Nairobi Kenya, 6-7 December 2012
Fibrocell Science ($FCSC) Rodman & Renshaw update October 2011
The document provides an update on Fibrocell Science's commercial launch of LAVIV, its cell therapy product. Key points include:
- 30 dermatologists have been trained so far and 43 tissue samples submitted for processing.
- Fibrocell plans to train over 200 dermatologists by year's end.
- The company emphasized additional potential indications beyond the initial approval for nasolabial folds.
- Analysts maintain a "Market Outperform" rating and $3.50 price target, estimating $1 billion in annual sales by 2019.
VENTURE CAPITAL
The document discusses venture capital and its role in fueling India's development by emphasizing different stages of financing and case studies. It provides statistics on venture capital investments in India compared to other countries and outlines the typical process that venture capitalists follow when evaluating and supporting companies. Challenges to venture capital in India include a lack of entrepreneurial culture and distance from resources, but the sector is growing and helping innovative startups secure funding.
Anteo Technologies - New York presentation 2015
- Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in healthcare, life sciences, and other industries.
- Mix&Go is a universal double-sided molecular coating that gently but strongly binds biomolecules to synthetic surfaces, addressing challenges in test miniaturization and cost reduction.
- Anteo's growth strategy includes licensing its intellectual property, expanding its coating technologies and applications, developing product pipelines that demonstrate Mix&Go's uses, exploring new market opportunities, and acquiring synergistic assets.
Running head GMO ETHICAL CONSIDERATIONS1 GMO ETHICAL CONSID.docx
Running head: GMO ETHICAL CONSIDERATIONS 1
GMO ETHICAL CONSIDERATIONS 6
GMO Ethical Considerations
Dustin Hunt
DeVry University
GMO Ethical Considerations
Introduction
Food security is a very important aspect of the economy of any country. In the desire and urge for countries to acquire food, securities have pushed countries into making use of various technologies in the agricultural sector to increase production. Among the technologies that have been adopted is the use of DNA technology which leads to the production of genetically modified foods. For the last about a quarter of a century, the issue of the DNA technology to produce the GM foods has raised a lot of controversies among individuals with some in support of the technology and many other against the use. The controversies raised have mainly been as a result of the ethical issues and concern that surround this topic. The individuals that support the use of technologies cite the lowered cost of food production, efficiency as well as more production. For those that are against the technology, they raise various ethical concerns such as health concerns, contaminations as well as environmental risks as is going to be discussed in this paper.
Analysis considers the impact of the technology on humanity.
The ethics that concern the issue of GMOs are mainly defined on the basis of the virtue vs. the vice (Piguet & Poindron, 2012). The set of ethical concerns that we are going first to focus on is mainly related to the consequences that born from the use of the GM foods. The consequences caused by the GM foods face a very major basis of the argument on whether the GM foods are right or wrong and whether or not they should be advocated. The questions to be answered in this are whether or not the GM foods have negative or positive effects.
Despite the fact that most scientist still holds that the GM foods are safe for consumption, and they do not pose any risk to the health of the consumers, there are still numerous health concerns that result in the consumption of GM foods, and this acts as a major ethical concern. The first such concern is allergies. The GM food is said to be related to the triggering of allergies in individuals. This is because the gene that is used to modify the plants could be extracted from an organism that is allergenic. When placed into a plant which initially does not cause its allergies, an allergen is added, and thus, the plant now poses the danger of allergies to consumers. When consumed by individuals they may, as a result, suffer allergic reactions. For individuals whose genes are not compatible with the genes used for modification, new allergies may also arise.
The second ethical concern that is also based on the consequences of the GM food is the diseases. GM foods also pose the risk of disease to their consumers. The modifications of the plants are sometimes done with bacteria and virus DNAs; there is the risk of new disease that is ...
NAMIC Management Conference, June 25, 2012
Investment Perspectives presentation for insurers interested in improving their investment process and, thus, their investment results.
Nexant - From the ground up constructing a multiproduct portfolio in biorefi...
This document is a prospectus for a Nexant report titled "From the Ground Up: Constructing a Multiproduct Portfolio in Biorefining". The report will analyze the economic competitiveness of different biorefining schemes through cost of production modeling and projections. It will explore available feedstocks, intermediates, and downstream processing technologies for locations in North America, South America, Western Europe, and Asia Pacific. The scope covers technologies for converting feedstocks like corn, sugarcane, and cellulosic biomass into fuels, chemicals, and other products. Subscribers will receive the cost modeling tool and analysis to help evaluate potential biorefinery configurations and strategies.
Global supply chain management iCognitive
The document discusses five key supply chain trends facing companies and opportunities for improvement: 1) increased supply chain volatility requires improved flexibility, 2) globalization increases complexity that must be managed, 3) regional configurations can optimize costs, 4) risk management must span the entire supply chain, and 5) integration of supply chain functions is needed. Mobile, analytics, and social media will impact supply chains. Priorities for success include improved planning, flexibility, cost optimization, risk management, and integrated supply chain organizations.
Update on pig value chain development in Vietnam
This document summarizes the update on pig value chain development in Vietnam. It discusses (1) the importance of pigs in Vietnam due to rising incomes and pork consumption, smallholder production, and policy challenges; (2) projected increases in pork supply from large-scale producers; and (3) proposed priority outcomes, research outputs, activities, and gaps for the project from 2012-2014, which include assessing constraints, identifying best interventions, building capacity, and influencing development decisions.
NEOGEN MICH TECH Finish
Neogen Corporation is a well-managed company in the animal and food safety industry that is currently overvalued. A discounted cash flow valuation estimates Neogen's fair value at $19.07 per share, significantly below its current price of $48.16. Relative valuation using peers also indicates Neogen is overvalued. While Neogen has strong finances, reasonable growth projections do not justify its current share price given fundamental and relative valuations show it is overvalued.
Luminex Q1 2011 Earnings Call
Luminex Corporation reported first quarter 2011 results with consolidated revenue of $43.3 million, a 30% increase over the first quarter of 2010. Gross margin increased 250 basis points to 71%. Net income was $4.5 million or $0.11 per diluted share, compared to $1.9 million or $0.05 per share in the first quarter of 2010. Operating income increased by $4.5 million to $8.3 million, representing 19% of consolidated revenue.
FERMA Seminar - Frank Baron - The Asian Perspective
This document summarizes the results of a survey of 50 risk managers in Asia-Pacific. [1] Market risk, competition/partnerships, and catastrophic events were identified as the top risks. [2] Most risk managers report to the CEO/C-level executives and see their primary objective as identifying and managing major risks. [3] While coordination between risk functions exists, further integration is needed.
2011 global-ce-management-survey
Global resources for customer experience are concentrated in certain regions and industries:
- North America and the UK currently allocate the most resources, but interest is growing in countries like Brazil, China, and India.
- Telecommunications, banking, retail, and IT services receive over 60% of resources allocated to customer experience globally.
- Within countries, resources are often concentrated among the "Big 4" industries of telecommunications, banking, retail, and IT services, though more mature markets are seeing diversification into other sectors.
- Emerging industries showing innovation and investment in customer experience include airlines, motor, and software.
CAACB Overview
An overview of the Industry Consortium on Adventitious Agent Contamination in Biomanufacturing - Administered by the Center for Biomedical Innovation at Massachusetts Institute of Technology
Similar to Case question of roche (20)
Anteo Diagnostics ASX Spotlight Presentation March 2014
Anteo Diagnostics ASX Spotlight Presentation March 2014
Vietnam Smallholder Pigs Value Chain Component Situation Report 2012
Vietnam Smallholder Pigs Value Chain Component Situation Report 2012
Fibrocell Science ($FCSC) Rodman & Renshaw update October 2011
Fibrocell Science ($FCSC) Rodman & Renshaw update October 2011
Running head GMO ETHICAL CONSIDERATIONS1 GMO ETHICAL CONSID.docx
Running head GMO ETHICAL CONSIDERATIONS1 GMO ETHICAL CONSID.docx
Nexant - From the ground up constructing a multiproduct portfolio in biorefi...
Nexant - From the ground up constructing a multiproduct portfolio in biorefi...
FERMA Seminar - Frank Baron - The Asian Perspective
FERMA Seminar - Frank Baron - The Asian Perspective
More from Bimo Radityo
Mc donald’s
McDonald's began in 1940 when brothers Dick and Mac McDonald opened a restaurant in California. They introduced the "Speedee Service System" in 1948 which established fast food restaurant principles. The current corporation dates to 1955 when Ray Kroc franchised the first McDonald's restaurant in Illinois. McDonald's vision is to be the leading global fast food provider. Their mission is to be customers' favorite place to eat and improve operations to consistently serve delicious, high quality food. McDonald's values are represented by "Q.S.C. & V" which stand for quality, service, cleanliness, and value that makes customers smile. To maintain its position, McDonald's must improve menu options with healthier choices while expanding globally, especially in
Google
Dokumen tersebut membahas strategi bisnis Google pada tahun 2010 dalam menghadapi berbagai isu seperti pelanggaran privasi, regulasi pemerintah, dan persaingan dengan kompetitor. Google berupaya mempertahankan brand equity dan positioning-nya sebagai perusahaan inovatif dan bertanggung jawab sosial dengan menyesuaikan praktik bisnisnya sesuai regulasi negara tertentu yang menyangkut privasi warga negaranya.
Continental airlines inc. 2007
This document summarizes the history and operations of Continental Airlines from its founding in 1934 through 2007. It discusses Continental's bankruptcies and financial difficulties in the 1980s and 1990s, its turnaround in the 2000s, and its competitors and market share. The document also outlines Continental's "Go Forward Plan" strategy with goals around profitability, cost reduction, reliability, and employee treatment. It raises several questions about Continental's strategies regarding low-cost carriers, other major airlines, regional jet service, service quality, international routes, fuel costs, online booking, and the EU-US Open Skies treaty.
Autocare pte ltd
Autocare Pte Ltd beroperasi sejak 1973 dengan sistem franchise dari perusahaan Ziebart asal Amerika Serikat. Perusahaan ini menawarkan jasa perlindungan karat, pelindung cat, dan pelindung kain interior mobil. Namun, bisnis ini mengalami penurunan pada 1983-1985 akibat resesi ekonomi. Dokumen ini membahas tentang ukuran pasar dan pertumbuhan bisnis perlindungan karat mobil di Singapura, kekuatan dan kelemahan Autocare, serta strategi mas
Case coca cola
Coca-Cola developed the BreakMate vending machine to make soft drinks more easily accessible to employees. The BreakMate was distributed through partners who had direct access to business customers. It was tested successfully in 30 cities across the U.S. and abroad. The BreakMate led to a $8 billion increase in Coca-Cola's soft drink sales by making their products more readily available in offices. It provided a long-term solution for businesses by offering machine maintenance and guarantees.
Presentation1
Dokumen tersebut membahas strategi perusahaan game konsol untuk meningkatkan daya saingnya dengan melakukan inovasi produk, mengembangkan produk baru, dan memperbanyak kerja sama dengan developer game terkemuka.
More from Bimo Radityo (10)
Case question of roche
- 1. Case Question of Roche
- 2. Assume Genentech has 1,052 million share outstanding : 1. Why is roche seeking to acquire 44 % of genetech it doesn’t own ? 2. From roche’s point of view, what are the advantages of owning 100 % of genetech ? What are the risk ? 3. As a majority shareholder of genetech, what responsibilities does Roche have to the minority shareholder ? 4. As of June 2008, what is the value of the sinergy roche anticipates from merger with genetech ? 5. Assess the value of sinergies per share of genetech ! ( use weighted average cost of capital 9 % )
- 3. Assume Genentech has 1,052 million share outstanding : Based on DCF valuation technique, what range of value is reasonable for genetech as stand alone company in june 2008 ) use wacc 9 % assume genetech has 7 billion usd cash, ( ignore value of sinergy )
- 4. Assume Genentech has 1,052 million share outstanding : • Based on DCF valuation technique, what range of value is reasonable for genetech as stand alone company in june 2008 ) use wacc 9 % assume genetech has 7 billion usd cash, ( ignore value of sinergy ) • What does the analysis of of comparable companies ( exhibit 12,13,14 ) indicate about genetech’s value within the range established in question above ? • How has the financial crisis affected the genetech’s value ? What change the assumption occured between jun 2008 and january 2009 ? • How did Genetech Board and management respond to Roche’s offer of 89 per share ?